Noninvasive Monitoring of Breast Cancer During Neoadjuvant Chemotherapy Using Optical Tomography with Ultrasound Localization

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2008 Sep 25

PMID 18813360

Citations 49

Authors

Quing Zhu

Susan Tannenbaum

Poornima Hegde

Mark Kane

Chen Xu

Scott H Kurtzman

Affiliations

Soon will be listed here.

Abstract

The purposes of this study were 1) to investigate the feasibility of using optical tomography in the near-infrared (NIR) spectrum combined with ultrasound (US) localization (NIR/US) in monitoring tumor vascular changes and assessing tumor pathological response during chemotherapy and 2) to compare the accuracy of NIR/US with magnetic resonance imaging (MRI) in predicting residual cancer after neoadjuvant chemotherapy. Eleven female patients were studied during treatments with a combined imager consisting of a commercially available US system coupled to an NIR imager. Contrast-enhanced MRI was performed before treatment and surgery. Tumor vascular content was assessed based on total hemoglobin concentration and volume obtained from NIR data. A percentage blood volume index (%BVI) was calculated as the percentage ratio of the product of total hemoglobin concentration and volume normalized to pretreatment values. At treatment completion, pathologic assessment revealed three response groups: complete or near-complete responders (A), partial responders (B), and nonresponders (C). The mean %BVIs of groups A, B, and C at the treatment completion were 29.1 +/- 6.9%, 46.3 +/- 3.7%, and 86.8 +/- 30.1%, respectively (differences statistically significant, P < .04). At the end of cycle 2, the %BVI of group A was noticeably lower than that of the partial (P = .091) and nonresponder groups (P = .075). Both NIR/US and MRI were equally effective in distinguishing different response groups in this pilot study. Our initial findings indicate that NIR/US using %BVI can be used during chemotherapy to repeatedly monitor tumor vascular changes. NIR/US also may evaluate pathologic response during treatment allowing for tailoring therapies to response.

Citing Articles

Ultrafast power doppler ultrasound enables longitudinal tracking of vascular changes that correlate with immune response after radiotherapy.

Martello S, Xia J, Kusunose J, Hacker B, Mayeaux M, Lin E Theranostics. 2024; 14(18):6883-6896.

PMID: 39629131 PMC: 11610147. DOI: 10.7150/thno.97759.

Monte Carlo simulation of spatial frequency domain imaging for breast tumors during compression.

Robbins C, Qian K, Zhang Y, Kainerstorfer J J Biomed Opt. 2024; 29(9):096001.

PMID: 39282216 PMC: 11399730. DOI: 10.1117/1.JBO.29.9.096001.

Performance assessment of MRI guided continuous wave near-infrared spectral tomography for breast imaging.

Feng J, Jiang S, Pogue B, Paulsen K Biomed Opt Express. 2022; 12(12):7657-7672.

PMID: 35003858 PMC: 8713687. DOI: 10.1364/BOE.444131.

Enhanced diffuse optical tomographic reconstruction using concurrent ultrasound information.

Di Sciacca G, Di Sieno L, Farina A, Lanka P, Venturini E, Panizza P Philos Trans A Math Phys Eng Sci. 2021; 379(2204):20200195.

PMID: 34218668 PMC: 8255947. DOI: 10.1098/rsta.2020.0195.

An Automated Preprocessing Method for Diffuse Optical Tomography to Improve Breast Cancer Diagnosis.

Althobaiti M, Vavadi H, Zhu Q Technol Cancer Res Treat. 2018; 17:1533033818802791.

PMID: 30278830 PMC: 6170968. DOI: 10.1177/1533033818802791.

References

Shah N, Gibbs J, Wolverton D, Cerussi A, Hylton N, Tromberg B . Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neoadjuvant chemotherapy: a case study. J Biomed Opt. 2005; 10(5):051503. DOI: 10.1117/1.2070147. View

Sullivan D . Molecular imaging in oncology. Ann Oncol. 2006; 17 Suppl 10:x287-92. DOI: 10.1093/annonc/mdl275. View

Makris A, Powles T, Kakolyris S, Dowsett M, Ashley S, Harris A . Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer. 1999; 85(9):1996-2000. DOI: 10.1002/(sici)1097-0142(19990501)85:9<1996::aid-cncr17>3.0.co;2-h. View

Floery D, Helbich T, Riedl C, Jaromi S, Weber M, Leodolter S . Characterization of benign and malignant breast lesions with computed tomography laser mammography (CTLM): initial experience. Invest Radiol. 2005; 40(6):328-35. DOI: 10.1097/01.rli.0000164487.60548.28. View

Weidner N, Carroll P, Flax J, BLUMENFELD W, Folkman J . Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993; 143(2):401-9. PMC: 1887042. View

Spinelli L, Torricelli A, Pifferi A, Taroni P, Danesini G, Cubeddu R . Characterization of female breast lesions from multi-wavelength time-resolved optical mammography. Phys Med Biol. 2005; 50(11):2489-502. DOI: 10.1088/0031-9155/50/11/004. View

Schmitz C, Klemer D, Hardin R, Katz M, Pei Y, Graber H . Design and implementation of dynamic near-infrared optical tomographic imaging instrumentation for simultaneous dual-breast measurements. Appl Opt. 2005; 44(11):2140-53. DOI: 10.1364/ao.44.002140. View

Athanasiou A, Vanel D, Balleyguier C, Fournier L, Mathieu M, Delaloge S . Dynamic optical breast imaging: a new technique to visualise breast vessels: comparison with breast MRI and preliminary results. Eur J Radiol. 2005; 54(1):72-9. DOI: 10.1016/j.ejrad.2004.11.022. View

Brooksby B, Pogue B, Jiang S, Dehghani H, Srinivasan S, Kogel C . Imaging breast adipose and fibroglandular tissue molecular signatures by using hybrid MRI-guided near-infrared spectral tomography. Proc Natl Acad Sci U S A. 2006; 103(23):8828-33. PMC: 1482663. DOI: 10.1073/pnas.0509636103. View

10.

Smith I, Welch A, Hutcheon A, Miller I, Payne S, Chilcott F . Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000; 18(8):1676-88. DOI: 10.1200/JCO.2000.18.8.1676. View

11.

DeMartini W, Lehman C, Partridge S . Breast MRI for cancer detection and characterization: a review of evidence-based clinical applications. Acad Radiol. 2008; 15(4):408-16. DOI: 10.1016/j.acra.2007.11.006. View

12.

Chance B, Nioka S, Zhang J, Conant E, Hwang E, Briest S . Breast cancer detection based on incremental biochemical and physiological properties of breast cancers: a six-year, two-site study. Acad Radiol. 2005; 12(8):925-33. DOI: 10.1016/j.acra.2005.04.016. View

13.

Bear H, Anderson S, Smith R, Geyer Jr C, Mamounas E, Fisher B . Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006; 24(13):2019-27. DOI: 10.1200/JCO.2005.04.1665. View

14.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

15.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

16.

Padhani A, Hayes C, Assersohn L, Powles T, Makris A, Suckling J . Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology. 2006; 239(2):361-74. DOI: 10.1148/radiol.2392021099. View

17.

Weatherall P, Evans G, Metzger G, Saborrian M, Leitch A . MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation. J Magn Reson Imaging. 2001; 13(6):868-75. DOI: 10.1002/jmri.1124. View

18.

Carey L, Dees E, Sawyer L, Gatti L, Moore D, Collichio F . The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13(8):2329-34. DOI: 10.1158/1078-0432.CCR-06-1109. View

19.

Ntziachristos V, Yodh A, Schnall M, Chance B . MRI-guided diffuse optical spectroscopy of malignant and benign breast lesions. Neoplasia. 2002; 4(4):347-54. PMC: 1661680. DOI: 10.1038/sj.neo.7900244. View

20.

Zhu Q, Huang M, Chen N, Zarfos K, Jagjivan B, Kane M . Ultrasound-guided optical tomographic imaging of malignant and benign breast lesions: initial clinical results of 19 cases. Neoplasia. 2003; 5(5):379-88. PMC: 1502608. DOI: 10.1016/s1476-5586(03)80040-4. View